Ventana Biotech, Inc. (VNTA) Stock Price & Analysis
Ventana Biotech, Inc. (VNTA) — price $0.04 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Ventana Biotech, Inc. · VNTA
Ventana Biotech, Inc. is a development-stage biotech company focused on identifying, acquiring, developing, and commercializing intellectual property for personalized medicine, particularly in anti-obesity and related illnesses.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.04 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0316 – $0.0649 | |
| Price / earnings (trailing) | 30.00 | |
| Shares traded on the day | 20.7K |
Price & events
Other perspectives
Council score for Ventana Biotech (VNTA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: May 26, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Ventana Biotech (VNTA), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ventana Biotech, Inc. (VNTA) is the company analyzed here. It employs 1 people and is led by Stephen Replin. In Q3 FY2025 it reported revenue of $47,721 and net income of $31,931.
What do the latest results show for Ventana Biotech (VNTA)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $47,721.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $47,721 | $31,931 | $0.0006 (diluted) |
| Q4 FY2025 | $801 | -$1,597 | $0.00 (diluted) |
| Q2 FY2025 | $65,255 | $56,640 | $0.0010 (diluted) |
| Q1 FY2025 | $800 | -$835 | $0.00 (diluted) |
What are the financial strengths and risks for Ventana Biotech (VNTA)?
Short answer · as of
Trailing ratios: earnings yield 3.3%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VNTA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported VNTA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Ventana Biotech Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the VNTA research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is VNTA a good stock to buy?
Stock Expert AI does not rate VNTA buy, sell or hold. Ventana Biotech, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the VNTA stock price today?
The last price recorded for Ventana Biotech, Inc. (VNTA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for VNTA?
The main risks for Ventana Biotech, Inc. are multifaceted, stemming from its status as a development-stage biotech company and its classification as an OTC-traded 'Shell Company.'
What are the key factors to evaluate for VNTA?
Evaluate VNTA on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Dividend Policy: The company does not currently offer a dividend yield, consistent with its status as a development-stage entity focused on reinvesting any capital into product development. Not financial advice.
How frequently does VNTA data refresh on this page?
VNTA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven VNTA's recent stock price performance?
Ventana Biotech, Inc. (VNTA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary intellectual property for a unique chewing gum formulation targeting obesity and metabolic disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VNTA overvalued or undervalued right now?
The trailing P/E of Ventana Biotech, Inc. (VNTA) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VNTA before investing?
Before investing in Ventana Biotech, Inc. (VNTA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 8 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com